

1 **Clinical Practice Guideline:** **Videonystagmography (VNG)**

2
3 **Date of Implementation:** **July 13, 2006**

4
5 **Product:** **Specialty**

6
7
8 **POLICY**

9 American Specialty Health – Specialty (ASH) clinical committees have determined that
10 Videonystagmography (VNG) for the diagnosis and monitoring during rehabilitation of
11 vestibular disorders such as benign paroxysmal positional vertigo, has diagnostic utility,
12 is professionally recognized and poses no health and safety risk. When used for other
13 purposes, VNG has insufficient evidence to establish clinical effectiveness, does not have
14 an established benefit:risk profile, poses a health and safety risk through substantial risk
15 of both substitution harm and labeling effects, and is considered to be scientifically
16 plausible. For more information, see ASHA policy *Techniques and Procedures Not*
17 *Widely Supported as Evidence Based – CPG 133.*

18
19 **PROCESS AND DEFINITIONS**

20 When developing, reviewing, and approving clinical policy, ASH peer-review
21 committees consider whether the technique/procedure:

- 22 • Is established as having diagnostic utility by:
- 23 ○ Scientific information published in an acceptable peer-reviewed clinical
24 science resource, and
- 25 ○ The consensus opinion of the Evidence Evaluation Committee (EEC)
26 when available;
- 27 • Is professionally recognized by:
- 28 ○ Inclusion in the educational standards accepted by the majority of the
29 professions' educational institutions,
- 30 ○ Wide acceptance and use of the practice, and
- 31 ○ Recommendations for use made by healthcare practitioners practicing in
32 the relevant clinical area;
- 33 • Poses a health and safety risk; and
- 34 • Is plausible or implausible
- 35 ○ A belief, theory, or mechanism of health and disease that can be
36 explained within the existing framework of scientific methods, reasoning
37 and available knowledge is considered plausible.
- 38 ○ A treatment intervention or diagnostic procedure that requires the
39 existence of forces, mechanisms, or biological processes that are not
40 known to exist within the current framework of scientific methods,
41 reasoning and available knowledge is considered implausible.

1 **Substitution harm (indirect harm):** Compromised clinical outcomes caused by:

- 2 • Utilizing a specific diagnostic or therapeutic procedure when the safety,
3 clinical effectiveness, or diagnostic utility is either *unknown* or is known to
4 be unsafe, ineffective, or of no diagnostic utility, *instead of* a diagnostic or
5 therapeutic procedure known to be safe, be clinically effective, or to have
6 diagnostic utility; or
- 7 • The utilization of a diagnostic or therapeutic procedure that is substantially
8 less effective or safe than another procedure with established safety, and
9 clinical effectiveness or utility.

10 **Labeling effects (non-specific harm):** The harm that results from identifying in a
11 patient a condition or a finding that is not clinically valid.

12 **Safe:** The terms “safe” and “safety,” are used only with specific reference to the
13 absence of direct harm. Direct harm would include any injury to a patient caused
14 by the mechanical, thermal, biological, chemical, pharmacological, electrical,
15 electromagnetic, or psycho-dynamic properties of a diagnostic or therapeutic
16 procedure, and as such, the procedure would be considered unsafe.

17 **Direct harm:** Any injury to a patient caused by the mechanical, thermal, biological,
18 chemical, pharmacological, electrical, electromagnetic, or psycho-dynamic
19 properties of a diagnostic or therapeutic procedure.

20 **Benefit versus risk profile:** The relative effectiveness or utility of a therapeutic
21 intervention or diagnostic procedure versus its potential for direct harm.

- 22 • Positive (benefits outweigh risks),
- 23 • Negative (risks outweigh benefits), or
- 24 • Equivocal (available information is inconclusive).

25 **Description/Background**

26 Videonystagmography (VNG) involves testing the nystagmus or eye jerks using a video
27 camera. A patient typically wears a specialized pair of goggles with a miniaturized
28 camera lens attached that record and analyze ocular stability and movements during a
29 variety of motions. Additionally, hot and cold air may be funneled into the ear to assess
30 the balance mechanism related to the specific areas of the brain that control their
31 functions. Many use VNG to diagnose and assist in rehabilitating vestibular disorders
32 such as balance problems related to vestibular dysfunction [e.g., benign paroxysmal
33 positional vertigo (BPPV)]. Other practitioners use VNG to identify cerebello-vestibular
34 dysfunction (CV), which proponents attribute to causing many conditions, including
35 learning disabilities, phobias, anxiety, scoliosis, and movement disorders.

1 Advocates of this broadened use claim VNG analysis combined with neurophysiological
 2 examination can allow a greater understanding of the underlying dysfunction and provide
 3 for a more specific treatment protocol to treat behavioral conditions such as attention
 4 deficit/hyperactivity disorder (ADHD).

5
 6 VNG is not considered to cause direct harm as a result of specific diagnostic or treatment
 7 effects. However, its experimental and investigational use, as described above, may cause
 8 indirect harm by delaying appropriate diagnostic testing and treatment (substitution or
 9 labeling effects).

10 **Evidence and Research**

11 A review of the literature supports the use of VNG to diagnose and assist in measuring
 12 the results while rehabilitating vestibular-related disorders such as BPPV. Although no
 13 clinical studies of VNG's validity as a diagnostic tool were located, it is clear from the
 14 medical literature that VNG is an accepted and useful tool for evaluating vestibular
 15 disorders (Maslovara et al., 2014; Chen et al., 2000; Frisina et al., 2000; Oas, 2001;
 16 Perez, 2003; Uneri and Turkdogan, 2003; Vitte et al., 1995). However, the research
 17 literature does not support VNG's broader use as a diagnostic tool for any other
 18 conditions such as ADHD, phobias, etc. (Levinson, 1988; Levinson, 1989; Levinson,
 19 1990; Polatajko, 1985; Polatajko, 1987).

21 **References**

- 22
 23 Chen, C. W., Young, Y. H., & Wu, C. H. (2000). Vestibular neuritis: three-dimensional
 24 videonystagmography and vestibular evoked myogenic potential results. *Acta*
 25 *Otolaryngologica*, 120(7), 845-848.
 26
 27 Frisina, A., Piazza, F., & Quaranta, N. (2000). [Infrared videonystagmography in
 28 vestibular diagnosis]. *Acta Biomedica Ateneo Parmense*, 71(5), 193-199.
 29
 30 Levinson, H. N. (1988). The cerebellar-vestibular basis of learning disabilities in
 31 children, adolescents and adults: hypothesis and study. *Perceptual and Motor Skills*,
 32 67(3), 983-1006.
 33
 34 Levinson, H. N. (1989). A cerebellar-vestibular explanation for fears/phobias: hypothesis
 35 and study. *Perceptual and Motor Skills*, 68(1), 67-84.
 36
 37 Levinson, H. N. (1990). The diagnostic value of cerebellar-vestibular tests in detecting
 38 learning disabilities, dyslexia, and attention deficit disorder. *Perceptual and Motor*
 39 *Skills*, 71(1), 67-82.

- 1 Maslovara S, Vešligaj T, Butković Soldo S, Pajić-Penavić I, Maslovara K, Mirošević
2 Zubonja T, Soldo A. Importance of accurate diagnosis in benign paroxysmal
3 positional vertigo (BPPV) therapy. *Med Glas (Zenica)*. 2014;11(2):300-6.
4
- 5 Oas, J. G. (2001). Benign paroxysmal positional vertigo: a clinician's perspective. *Annals
6 of the New York Academy of Sciences*, 942, 201-209.
7
- 8 Perez, N. (2003). Vibration induced nystagmus in normal subjects and in patients with
9 dizziness. A videonystagmography study. *Revue de Laryngologie Otologie
10 Rhinologie (Bord)*, 124(2), 85-90.
11
- 12 Polatajko, H. J. (1985). A critical look at vestibular dysfunction in learning-disabled
13 children. *Developmental Medicine and Child Neurology*, 27(3), 283-292.
14
- 15 Polatajko, H. J. (1987). Visual-ocular control of normal and learning-disabled children.
16 *Developmental Medicine and Child Neurology*, 29(4), 477-485.
17
- 18 Uneri, A., & Turkdogan, D. (2003). Evaluation of vestibular functions in children with
19 vertigo attacks. *Archives of Diseases in Childhood*, 88(6), 510-511.
20
- 21 Vitte, E., Semont, A., Freyss, G., & Soudant, J. (1995). Videonystagmoscopy: its use in
22 the clinical vestibular laboratory. *Acta Otolaryngologica Supplement*, 520 Pt 2, 423-
23 426.